Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00114816 |
Recruitment Status :
Completed
First Posted : June 20, 2005
Last Update Posted : May 21, 2007
|
Sponsor:
Finnish Breast Cancer Group
Collaborators:
Hoffmann-La Roche
Sanofi
AstraZeneca
Information provided by:
Finnish Breast Cancer Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Primary Completion Date : | No date given |
Actual Study Completion Date : | April 2007 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):